Japan Approvals Include World Firsts For Romosozumab, Spinal Injury Cell Therapy
Executive Summary
The latest group of new product approvals in Japan includes the first marketing clearances worldwide for fracture-reducing osteoporosis antibody romosozumab and a stem cell-based therapy for spinal cord injury, as well as two new Daiichi drugs and Pfizer's lung cancer therapy dacomitinib.
You may also be interested in...
Amgen Launches Evenity For High-Risk Osteoporosis At $21,900 List Price
Amgen EVP Murdo Gordon highlighted the unmet need for women at high risk, including those with a prior fracture. At $1,825 per month or $21,900 for a one-year course in the US, he says Evenity's cost is much lower versus competing 18- and 24-month anabolic agents.
PMDA Chief Defends Japan Spinal Cord Therapy Approval
The head of Japan’s drug and device regulator has defended and supported the country’s recent world-first decision to grant approval to a novel cell-based therapy for spinal cord injuries, saying that patient considerations came first.
Surprising SanBio/Sumitomo Stroke Stumble Slams Stocks
Mesenchymal stem cell-based therapy's missed Phase IIb endpoint in stroke prompts both an assessment of future development plans and a precipitous fall in developers' stocks.